Prediction of response to biological treatment with monoclonal antibodies in severe asthma
Authors:
- 1 September 2020
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 179, 113978
Abstract
No abstract availableKeywords
Funding Information
- Medical Centre Leeuwarden Science Fund, the Netherlands
This publication has 97 references indexed in Scilit:
- The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysisJournal of Allergy and Clinical Immunology, 2013
- The Transcription Factor GATA-3 Controls Cell Fate and Maintenance of Type 2 Innate Lymphoid CellsImmunity, 2012
- Susceptibility and immunity to helminth parasitesCurrent Opinion in Immunology, 2012
- An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiationInternational Immunology, 2011
- IgE, mast cells, basophils, and eosinophilsJournal of Allergy and Clinical Immunology, 2010
- Overview of Therapeutic Drug MonitoringThe Korean Journal of Internal Medicine, 2009
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- THE HIGH-AFFINITY IgE RECEPTOR (FcεRI): From Physiology to PathologyAnnual Review of Immunology, 1999